Preclinical data demonstrate potential application of anti-siglec-15 treatment in bone disease

Beltsville, md., sept. 05, 2023 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of preclinical data demonstrating that treatment with nc605, a novel anti-siglec-15 (s15) antibody, reduced bone loss and enhanced bone formation and quality following immobilization in an experimental animal model of acute spinal cord injury (sci), at the 2023 military health system research symposium (mhsrs).
NXTC Ratings Summary
NXTC Quant Ranking